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Cellular transformation leads to rapid cell proliferation that causes a global disease called cancer. Breast 
cancer is the second most frequent group that affects primarily women. Disease progression is stimulated 
by the female sex hormone estrogen. This hormone affects cells via estrogen receptor signalization, for 
example, by changes in proliferation, angiogenesis, apoptosis, and differentiation. The estrogen signaling 
pathway also alters breast cancer cell metabolism.  The inhibition of estrogen signalization is commonly 
used in cancer treatment. Nonetheless, some tumors show resistance to the treatment and increase the 
need for new targets of therapy which can be found among the changes in breast cancer cells metabolism. 
This thesis introduces more closely the topic of breast cancer and the effect of estrogen receptors. 
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Abstrakt 
Bunečná transformácia vedie k nádorovému bujnenie, ktoré spôsobuje globálne ochorenie, nazývané 
rakovina. Rakovina prsníka predstavuje druhú najviac zastúpenú skupinu postihujúcu najmä ženy. Postup 
ochorenia je stimulovaný ženským pohlavným hormónom estrogénom. Tento hormón ovplyvňuje bunku 
cez signalizáciu estrogénového receptoru, napríklad zmenami v proliferácii, angiogenézii, apoptóze 
a diferenciácii. Táto signálna dráha ovplyvňuje aj metabolizmus buniek rakoviny prsníka. V liečbe sa 
využíva inhibícia práve estrogénovej  signalizácie. Avšak, niektoré tumory sú voči tejto terapii rezistentné 
a je potrebné hľadať nové ciele terapie, ktorými môžu byť zmeny v metabolizme buniek rakoviny prsníka. 
Tato práca bližšie zoznamuje s tematikou rakoviny prsníka a vplyvu estrogénového receptoru.  
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Cancer is a serious disease endangering the lives of millions of people around the world. Breast cancer 
belongs to the group of diseases that are caused by cell transformation and rapid proliferation. The most 
endangered in a population are women, especially in the premenopausal period of life. According to 
WHO, breast cancer was the second common cancer that causes death with 2,09 million cases worldwide 
in 2018.   
Breast cancer cells differ from normal tissue cells in many ways. These cells are strongly edited to 
divide above the average limit of growth. This ability leads to a pathological state of cells that may cause 
metastasis. The metastasis is a process of the cancer cluster cell traveling that enables dispersion through 
vessels of an organism to distant parts of the body. This cancer cell spreading is the most life-threatening 
phase of cancer disease.   
One of the driving forces of carcinogenesis is a female sex hormone called estrogen. This steroid 
molecule is important for female body development, regulation of female period cycle and other 
processes. Estrogen impacts breast cancer formation via estrogen receptors. Estrogen receptor is a 
protein consisted of six domains. Receptors can be activated via two pathways: ligand-dependent and 
ligand-independent, respectively. As a result of these two pathways, the receptor has several possible 
signaling cascades that affect cell functioning.   
The characteristic feature of cancer cells is their altered metabolism. Breast cancer cell energetics is 
also influenced by estrogen signaling cascade. This way the cancer cell gains the advantage of fast 
proliferation. Thanks to the specific metabolic alterations, cells can be selectively targeted by diverse 
therapies.  
Some breast cancer subtypes are effectively treated by focusing on estrogen receptor signal 
inhibition. The treatment is called hormone therapy. This thesis summarizes the knowledge about the 
function of estrogen signaling in breast cancer cells and its influence on cells, its metabolism and the role 




2. Cell transformation 
Cancer, as a systemic disease, originates by neoplastic transformation within a single cell; under some 
conditions, normal cells can undertake processes leading to transformation into neoplastic cells. The 
process of carcinogenesis includes several sequential events1. Several neoplastic cells survive and 
proliferate past normal cells and create a foundation for malignancy2. Combination of several genomic 
changes lead to uncontrolled cell growth, typically gain-of-function mutation of proto-oncogenes into 
oncogenes (e.g. H-RAS, ErbB2, PI3KCA, MYC) and inactivation of tumor suppressor genes (e.g. RB, CHK2, 
PTEN, TP53, RAD50)3.  
Transformed cells attain characteristic biological features which enable the cancer progression, called 
“hallmarks of cancer”2 (Fig.1.). Alterations in a genome may lead to the formation of "mutant" cells. Unlike 
normal cells, the proliferation of which is strictly under control, cancer cells deregulate proteins involved 
in the cell cycle. The activation of growth-stimulatory signals happens through the induction of 
proliferative signals, the release of mitogenic signals, and attenuation of cell growth down-regulators. 
Proteins involved in the process are basically tumor suppressor genes and they inhibit cell proliferation. 
For the subsequent growth, the tumor must avoid the natural cell attribute called contact inhibition. 
Contact inhibition means that proliferation is repressed to prevent an abnormal number of cells in the 
limited space and dense conditions. 
Another hallmark of transformed cells is the ability to avoid cell death. Proliferation can be accelerated 
to that extent an error in the cell cycle occurs and it may lead to apoptosis. Cell death can also be invoked 
from the outside. It is crucial for the cancer cell to inhibit the apoptotic pathway in order to survive and 
proliferate.  
Next, normal cells are programmed to avoid cell damage and to protect the organism by having a 
limited amount of growth and division cycles (Hayflick limit). Cancer cells must be immortalized which 
means that they must escape the Hayflick limit and enhance the replicative potential. With increasing cell 
numbers, nutritional demands are also increased, so growing tumor mass is forced to develop the new 
vasculatures in order to supply the cells with nutrients2. 
Immune system (IS) cells also play a role in cancer progression. Tumors are infiltrated by immune cells. 
These cells provide support for tumor survival. On the other hand, If the cell is transformed properly, 




2.1 Activation of invasion and metastasis 
The most dangerous and relevant hallmark of cancer cells is the ability to form a metastasis2. During 
the initial stages of cancer the primary tumor is formed; further stages include the activation of the 
metastatic cascade which consists of invasion, intravasation, the arrest of cancer cells, extravasation, and 
neovascularization4. Metastasis represents an increased risk for the patients; spreading cells to other 
parts of the body and formation of metastases brings poorer outcome and increased risk of death.  
The formation of metastasis is crucial for survival. This is how the tumor avoids metabolic and 
proliferative limitations5. There is also a correlation among metabolic flexibility and survival of metastases 
in distant tissue6. 
Metastatic process is described by clonal selection hypothesis, where a subpopulation of the cells in 
primary tumor forms a secondary tumor (Fig.2A)7. The theory is challenged nowadays by cancer stem cell 
models, where the same cell clones of pluripotent cells are responsible for primary and secondary tumors 
(Fig.2B)8.   
 
Fig.1. The hallmarks of cancer. The circle illustrates the unique 
abilities of cancer cells important to the progression of 








Invasion-metastatic cascade is a sequence of events happening in exact order. It starts with the local 
invasion through the extracellular matrix. Then, progressing cells penetrate blood or lymph vessels in a 
process called intravasation and are carried through the lymphatic or hematogenous system. Such cells 
are called circulating tumor cells (CTCs)9. The next step is the escape from the lumina of vessels to the 
parenchyma of distant tissue. The opposite action of intravasation is called extravasation. Before the 
arrival of the interspersed tumor cells from the primary site to neighboring tissue, it is crucial to pre-form 
the pre-metastatic niche for establishing metastasis10. The successful clones now create small nodes that 
grow over time2. 
The process of metastasis also includes changes in cells potency. The epithelial-mesenchymal 
transition (EMT) is the initial step in the metastatic process. In the process of EMT epithelial phenotype is 
lost, the cell with the mesenchymal characteristics arise and consequently colonize distant tissue (Fig.3.). 
This cell can migrate11 due to a modification in the expression of adhesion molecules e.g. in E-cadherin, 
EpCAM, keratin-146. The reverse process of EMT, called mesenchymal-epithelial transformation (MET), is 
also necessary for metastasis in the matter of formation of a new tumor cluster11. Endothelial-
mesenchymal transition (EndMT) is the transformation of vascular endothelial cells to mesenchymal 
cells9. The cell surface is altered in a way independent on the contact with other cells and allows its 










Fig.2A. Clonal selection of 
the metastatic progression. 
Fig.2B. Stem cell model of 
metastatic progression.  




2.2 Metabolic changes in cancer cells 
Altered cancer metabolism is one of the hallmarks of cancer cells. Cancer cells have a considerably 
higher requirement for energy than non-transformed cells5. Because of higher rates of proliferation 
(essential for the formation of tumor mass) cell growth requires biosynthetic precursor and induce 
changes of cell energetic pathways, such as glycolysis, glutaminolysis, β-oxidation, de-novo fatty acid (FA) 
synthesis, serine synthesis, and others2.  
Alteration of metabolic pathways in cancer cells supports energy production. The main source of 
energy for the cell, the ATP molecules is preferably acquired from the aerobic glycolysis even if oxygen is 
present5,12; lactate is produced under aerobic conditions instead of channeling pyruvate to mitochondrial 
oxidation in Krebs cycle13. Incomplete oxidation of glucose into lactate offers cell 18 times less ATP/mol 
glucose than glycolysis with citric acid cycle and respiratory chain included, but it is about 100 times faster 
regarding the duration of both reaction pathways and that gives advantage to the transformed cells5. This 
metabolism generates an acidic environment which might support extracellular matrix (ECM) degradation 
and invasive phenotype5. 
  
Fig.3. The process of EMT. The transformed epithelial cell gradually loses 
contact with the surrounding cells and cell polarity. These cells have 
changed the shape and surface, so the adhesion is adjusted. Finally, this cell 




Moreover, alteration of metabolic pathways also supports cell growth by generating metabolic 
precursors for anabolic processes. The aerobic glycolysis provides important growth profit as a carbon 
source along with the energy source (Fig.3.). The building blocks acquired via glycolysis are important in 
highly proliferative cells and they are used as a base for nucleic acid synthesis and amino acid production5. 
Increase in glycolysis causes increased levels of intermediates such as glucose-6-phosphate that favors 
pentose phosphate pathway that generates reducing equivalents (NADPH) subsequently used in both 
redox homeostasis maintenance and FA biosynthesis. 3-phosphoglycerate produced in glycolysis is a 
precursor for the serine synthesis pathway and commonly used in cancer cells to support proliferation5. 
In a highly proliferative stage, the cells increase glycolytic and decrease oxidative metabolism. After, 
the highly proliferating cells become to be denser and more hypoxic the hypoxia-inducible factor-1 (HIF1) 
supplies the source of oxygen and nutrition by angiogenesis14. Then migration and metastasis could take 
place. These cells are exposed to oxidative stress and hypoxia that let them to stemness, angiogenesis 
and invasiveness, and metastatic potential. These cells are characterized by increased mitochondrial 
biogenesis of ATP. The metastatic capabilities of BC cells are ensured by PGC-1α-induced oxidative 
phosphorylation (OXPHOS) metabolism that is essential for tumor progression. In the phase of increased 
stem cell properties heterogeneity in bioenergetic properties is found. Some cells rely on glycolytic 
metabolism and some prefer OXPHOS metabolism14. 
Glutaminolysis is another altered metabolic pathway in cancer cells; 2-oxoglutarate is anaplerotically 
formed from glutamine and supports mitochondrial metabolism. Glutamine transporter (ASCT2) and 
glutaminase (GLS) are commonly upregulated enzymes in cancer cells leading to induction of 
glutaminolysis15. Krebs cycle of cancer cells is also altered; citrate is exported from mitochondria to 
support de-novo FA synthesis. We call this feature “truncated Krebs cycle”. 2-oxoglutarate is 
compensated by glutaminolysis. Glutamine is also used as an antioxidant in cells14.  
Among other mitochondrial alterations, cancer cells are often dependent on pyruvate carboxylase (PC) 
enzymes, which supports anaplerosis of both pyruvate carboxylation and glutaminolysis. For progression 
and surveillance of invasive and metastatic cells, it is important to maintain pyruvate cycling. The major 
TCA (tricarboxylic acid cycle) intermediates are exploited in metabolic pathways as biosynthesis of lipids, 
nucleic acids and some amino acids that correlates with cell proliferation. There is a correlation between 







Fig.4. Summary illustration of metabolic alterations in cancer cells. 
Taken from 14. 
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3. Breast cancer  
Breast cancer (BC) is a very common heterogeneous group of malignant diseases. In developed 
countries, carcinoma of breast belongs to the most frequent cause of death among women (there is 
variation between ethnic groups)16. The risk of breast cancer significantly increases during life, mostly in 
premenopausal women. This hormone-dependent disease prevails mainly in the female population, still, 
men could also be in danger17. Typical metastatic sites of breast cancer are the lung, liver, brain, or bone10. 
Every year 2.1 million women develop the disease worldwide18. In 2016 the incidence of BC in the 
Czech Republic was more than 130 cases per 100,000 of women, i.e. more than 7000 of newly diagnosed 
cases per year19. The percentage of 5-year survival after cancer for women with invasive BC is 90 %, 10-
year survival is about 83 %. The 5-year survival for cancer located only in the breast is 99 %, for the disease 
that is spread to lymph node the survival rate is lowered to 85 % and in case of the metastatic disease the 
survival rate is only 27 %20. 
3.1 Breast cancer classification 
We distinguish several groups of BC from a clinicopathological and genetic point of view21. 
Tumor progression of the breast carcinoma could be classified in terms of morphological features as 
ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC)10. The tissue of origin within the breast 
(the lobules or the ducts) also determines carcinoma type; the preinvasive in situ carcinomas are called 
depending on the origin as ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)22. DCIS phase 
of the mammary tumor is considered premalignant. Otherwise, the IDC stage tumor is an invasive phase, 
which includes migration to distant tissue. The main difference between these two stages is the loss of 
myoepithelial layer and BM in IDC21. Breast cancer progression is depicted in Fig. 5. 
By histological features such as the extent or spread, BC is classified by "Nottingham Grading System" 
into grades. Grade 1, the low-grade carcinoma is characterized as a well-differentiated tumor. Tumors 
that belongs to Grade 2 are moderately differentiated and are the intermediate grade carcinoma. And 
finally, Grade 3 are cancers with high grade, and these tumors are poorly differentiated23,24. 
Another clinical classification of BC stage is the TNM system. T stands for the tumor size and location; 
it could be in range 0-4 when T0 is tumor free, and T1-4 depends on tumor measure and range. N means 
node invasion and consist of 4 stages. N0-cancer cells did not invade lymph nodes, N1-3 nodes are 
invaded, 2 4-9, N3-more than 10 nodes. And finally, M is a measure of metastasis. M0 no metastatic 
cancer, M1 evidence of metastasis in a distant part of the body. Combining of T, N, M classification 
determines the stage of BC. There are 5 stages, 0-IV. 0 is known as DCIS (noninvasive carcinoma in situ) 





The molecular classification is based on differences in expression of hormone receptors26. According 
to this categorization, we distinguish less aggressive luminal-like that have two forms luminal A form and 
luminal B, HER2+, basal-like10, claudin-low(CL)27 and normal-like breast carcinomas28. 
Luminal A subgroup was characterized as a type with the highest expression of genes that mediate the 
effect of estrogen and the low expression of genes managing proliferation. Patients suffering from this 
type have the most positive clinical behavior29. 
Another luminal breast cancer type, luminal B tumors are characterized with lower levels of receptors 
for estrogen (ER) and progesterone (PR) than luminal A subtype, higher levels of proliferation cluster 
protein M KI67 and cell cycle-associated proteins (CCNB1 and MYBL2) and increased expression of growth 
factor receptor genes30. 
ERBB2/HER2+ group is known by overexpression of HER2, low expression of ER and associated 
genes29,31. 
Fig. 5. The normal mammary gland is characterized as well-organized layers of the cells piled up on 
each other. These layered cells are surrounded by randomly organized fibrillar collagen. There are also 
other cells needed for mammary homeostasis. After the unregulated proliferation of the epithelial cells in 
DCIS stage of BC, the cancer cells aggregate in the lumen and other changes of the tissue occur in the area 
of the mammary gland. After the lumen is almost completely full of transformed cells, the surrounding 
tissue is organized and represents the path for cancer cell transport. The cancer cells grow through the 
myoepithelial layer and BM. Edited from 21. 
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A basal-like subtype is also known as triple-negative breast cancer (TNBC). It is the heterogeneous 
group of tumors that have downregulated the expression of ER, PR, and HER226. These tumors also are 
BRCA1 mutation carriers, have aggressive feature including high proliferative capacity, high histologic 
grade, and frequent TP53 mutations. Along with HER2+ are considered as more aggressive subtypes with 
poor clinical outcome31.  
CL subgroup has the most enriched stem cell-like features among others followed by TNBC. The 
expression of PR and ER is higher than in TNBC, although low. Also, the P53 pathway is downregulated27. 
CL tumors lack in tight junction proteins (claudin 3, E-cadherin), downregulated the expression of luminal 
markers and upregulation of mesenchymal markers27.  
And finally, normal-like subtype has similar features as normal breast tissue28. 
3.2 Genetic background of breast carcinoma 
Diversity among subtypes of BC is characterized by differences in genetic alterations leading to specific 
tumor phenotype. To achieve this, cells must accumulate genomic alterations21. For instance, ER+ and 
HER2+ subtypes often carry some missense mutations; on the other hand, TNBC tumor has an elevated 
amount of nonsense, frameshift, and complex mutations. HER2+ and TNBC are enriched in the genomic 
rearrangements and copy number alterations21. 
The most common source of abnormal growth is genome instability. Mutations of BRCA1 are 
responsible for the hereditary form of breast cancer. The risk of BC is increase due to the mutation in one 
allele of this gene32. 
BRCA1 is a tumor suppressor gene which is normally responsible for maintaining genomic stability, 
DNA repair, cell cycle, and other processes33. BRCA1 protein is activated after the double-strand break of 
DNA. As a result, BRCA1 is phosphorylated by ataxia-telangiectasia mutated (ATM) kinase and the 
initiation of DNA repair through a sequence of actions proceeds. Phosphorylated BRCA1 recruit Rad50-
Mre11-NBS1 complex that binds to DNA. Also, an inactive complex BRCA2-Rad51 is activated and Rad51 





Other typical oncogenes and tumor suppressor genes responsible for breast carcinoma are, for 
example, in the alleles of the TP53 gene that encodes the tumor-suppressor protein p53 that interacts 
with RB1 protein. Their cooperation participates in the regulation of the cell cycle, cell repair, and 
apoptosis. 
EGFR and ERBB2 (Her-2/neu) gene encode an epidermal growth factor receptor, a cell surface protein 
called ErbB2. Its role is in cell adhesion, specialization, and motility of the cell. Overexpression of the gene 
brings many receptors to the cell surface that make a strong signal for dividing and rapid cell growth. It 
increases the risk of BC and metastasis.   
Also, CDH1 gene codes E-cadherin, the adhesion glycoprotein that is considered as a tumor suppressor 
in BC. Reduced expression of this transmembrane molecule is related to the metastatic transformation 
due to increased cell motility35. Furthermore, low DNA repair capacity (DRC) can be found among all types 
of BC and represents a risk of developing the disease, the lowest DRC is found in TNBC subtype36. 
Alterations in these and other genes represent the risk of development of BC. The most commonly 
mutated genes in breast cancer (over 4 % of frequency) are presented in Fig.7. 
  







3.3 Estrogen receptor 
Estrogen is a steroid hormone which originates from cholesterol molecule synthesized from LDL-
cholesterol. The main estrogens in the human body are estradiol, estrone, and estriol37. Organs that 
synthesizes estrogens are ovary, placenta, testes and adrenal cortex. Estrogen is needed for evolving 
secondary sex features and has an impact to almost all organs and tissue of a body including plasma lipid 
profiles, concentration of coagulator factors, insulin and glucose levels in the blood and nitric oxide 
synthesis. 
ER belongs to a group of nuclear receptors. Estrogen has a vast influence on organism e.g. 
development, migration, proliferation, and survival of targeted cells32. Pleiotropic action of estrogen 
induces changes in almost all body tissue. This action is mediated by estrogen receptors38.  
3.3.1 Structure of estrogen receptor 
The cellular localization of ERs is at the nucleus as well as at the plasmatic membrane/cytoplasm33,40. 
The membrane ER has the same structure as the nuclear ER. Localization to the plasma membrane is 
enabled due to the posttranslational modification of the receptor, the palmitoylation, which anchors 
receptor to the membrane, as palmitoyl residue increases the hydrophobicity of the protein32. 
The structure of ERα is illustrated in Fig.8. ERs consist of the six functional domains marked A-F. The A 
domain is located at the N-terminal end along with the B domain and is hypervariable among nuclear 
receptors. Its function is not clearly understood. B domain contains activation function 1 (AF-1)38. AF-1 
mediates both ligand-independent and dependent responses vary in type of cell, promotor38,41 and ligand-
specific manner. ERα contains serine residues that can be phosphorylated under specific conditions by 
several intracellular kinases. This action is regulated by growth factors such as epidermal growth factor, 
35,9 34,7
11,7 11,7




























Fig.7. Graph representing mutations in BC cells. Mutated genes in breast 
carcinoma (over 4 % of frequency) generated by cBIOPORTAL (6,100 samples 
with mutation data). 
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insulin-like growth factor or fibroblast growth factor. On the other hand, the AF-1 domain interacts with 
coactivators. AF-1 activates after the dimerization, DNA binding or contact with other proteins.  
The domains E and F are localized at the C-terminal end of the receptor. The E domain is known as a 
ligand binding domain (LBD). This large and complex region with a ligand-dependent activation function 
2 (AF-2) is organized to the shape of the hydrophobic pocket for the ligand38. The AF-2 region binds 
coregulators as well, contains the nuclear localization signal (NLS) and is responsible for the 
dimerization41. The F domain may modulate the recruitment of some partners of ERα and defines the 
balance of the agonist/antagonist for different ligands, mostly antiestrogens.  
Two zinc fingers at the domain C called a DNA binding domain (DBD), ensures the receptor binding to 
an estrogen responsive element (ERE) in the DNA sequence. This domain is the most conserved one. The 
zinc fingers are formed by tetrahedral coordination of two zinc ions with four cysteine residues. The first 
zinc finger lodges to the major groove of DNA. EREs, the sequence where zinc finger binds, is 13 bp 
consensus sequence GGTCAnnnTGACC, the inverted palindrome. It demonstrates the symmetrical 
binding of two monomers of ER dimer. The second zinc finger plays a role in creating the correct 
dimerization by recognizing proper spacing among the palindromic DNA element. The C domain is 
localized at the central region of the protein along with the D domain that represents a hinge area. The 
fragile region allows conformational changes of the protein during its interactions. The second NLS is 
located here and plays a role in crosstalk with transcription factors such as Sp1. Various posttranslational 




Fig.8. ERα organization 
The protein consists of functionally diverse domains: AF-1 with posttranslational 
modification sites for phosphorylation, DBD, hinge region (H) with another phosphorylation 
sites and NLS, LBD where the ligand (L), such as estrogen, binds and AF-2 that is ligand 
dependent. There are several cellular kinases responsible for posttranslational 




3.3.2 Intracellular estrogen signaling  
The pleiotropic effect of estrogen signaling is mediated by ER which has estrogens as the agonist41. 
The cells express two different isomer receptors, called ERα and ERβ32. 
ER has several pathways of signaling. The first one, genomic, is slow one (the effect comes within 
hours). The estrogen receptors have nuclear localization39,42. The genomic pathway starts with the 
estrogen binding to the ER and its transition to the nucleus42. 
LBD is in an “open conformation” while no ligand is bound. After the ligand binds to the receptor 
hydrophobic pocket, several remodeling processes take place. These changes modify the protein to the 
more compact state and the signaling may start38. After estradiol binding, two receptors dimerize and 
conform homodimer or heterodimer (αα, ββ, αβ)32. The genomic signaling pathway continues with the 
receptor translocation to the nucleus38.  
The action of ER in the nucleus has two different pathways. The classical one is by direct protein 
binding to DNA, to specific EREs sequences in the promoter regions of the targeted gene. The liganded ER 
recruits transcriptional co-factors and components of RNA polymerase II complex and altogether regulate 
the transcription of the targeted genes38,41.  
An alternative pathway runs without receptor direct binding to DNA. The liganded ER interacts by the 
protein-protein interaction with other transcription factors at promotors including Sp-1 and AP-1 
proteins, NfκB (Nuclear factor κB), GATA-141. Some of the estrogen-dependent genes contain nuclear 
hormone receptor SF1 and SF2 response elements instead of EREs32. 
The other possible way is nongenomic signaling with a rapid effect in a range from a few seconds to 
one minute39,42. These responses are ensured by ER that are localized at the cellular membrane where 
the important and fast signaling pathway starts. The steroid hormone signaling cascade is mediated by 
receptor induction which activates tyrosine kinases, MAPKs (mitogen-activated protein kinases), G-
proteins and modulates ion channels opening. Another option for inducing the signals is the allosteric 
modifications of receptor and/or structural and enzymatic proteins of the cell membrane. The non-
genomic pathway also affects transcription by phosphorylation of TFs.  
Integration of both nuclear and membrane-localized ER signaling creates unique action. The 
membrane ER signaling goes through cAMP-dependent protein kinase A (PKA) or MAPK and can affect 
the nuclear ER actions32. 
There is a correlation between ER and a growth factor (EGF, IGF, and insulin) signaling pathway. The 





















Fig.9. Estrogen receptor (ER) signaling pathways.  
Schematic visualization of known ER signaling cascades. The classical pathway of ER 
action is mediated by estradiol (E2). E2 binds to ER and affects transcription via ER 
dimerizing and directly binds to ERE on the promoter of the targeted gene. Another 
ligand-dependent pathway is an alternative genomic pathway. This pathway is ERE-
independent, and regulation is done via interactions with other transcription factors 
(TFs). Another ER action is mediated by interactions with transmembrane growth factor 
receptors such as EGFR, HER2 and insulin-like growth factor receptor (IGFR1). Their 
signaling cascades affect cell function. The nongenomic mechanism is mediated by E2 
interaction with ER at the cellular membrane that stars the signaling cascade in the cell 




3.3.3 ERα and ERβ  
ER has two isomers that are called ERα and ERβ. ERα is coded by NR3A1 (also called ESR1) gene and 
ERβ by NR3A2 (also called ESR2)38. The genes coding these proteins are located on other chromosomes 
in human genome32. 
 The expression and tissue distribution of the isomers differ. ERβ is more common in a normal human 
mammary gland than ERα44,45. ERβ is present at high concentrations in the nuclei of the myoepithelial 
cells. ERβ is also expressed in lymphocytes, stromal cells, and endothelial cells45. 
Contrarily, the ERα is localized mainly in epithelial cells lining ducts and lobules, specifically at the 
nuclei. ERα expression increases with age and is regulated by PR45.  
ERβ serves as a gatekeeper in cancer biology and slow down the tumor growth and inhibits its 
progression44. ERβ is responsible for the negative regulation of estrogen signaling antagonizes the 
transcriptional activity mediated via ERα, however, there are few exceptions, e.g. proliferative function, 
when ERβ can also act as an ERα agonist. Therefore,  it is considered that ERβ has a bifacial character44,46. 
The activity depends on ERα/ERβ ratio in such tissue47.   
3.3.4 Molecular targets of estrogen signaling 
ER pathways induce a wide number of responses that causes changes in almost all the organs and 
tissue of the body.  At the cellular level, proliferation is altered via non-genomic signaling through ERK-
related kinases42. The non-transcriptional PI3K/Akt (Phosphoinositide 3-kinases/protein kinase B) 
signaling pathway induced by 17-β-estradiol (E2) results in the increase of proliferation. Akt also affects 
the reduction of antiapoptotic signaling48. E2 promotes the human serine proteinase inhibitors serpin PI-
9 and influences the cell’s response to apoptosis induced by immune system49.  
Another role of estrogen is in the regulation of insulin sensitivity and glucose homeostasis in muscle 
and adipose tissue cells. In this peculiar case, ERα and ERβ have the opposite effect. ERβ action is 
diabetogenic by reducing the expression of GLUT4 that maintains glucose homeostasis in a body and its 
depletion leads to glucose tolerance cutback47. Furthermore, E2 affects the expression of an insulin 
receptor and affects the adipose tissue50.  
The gene transcription of many NOD-like(nucleotide-binding oligomerization domain-like) receptors 
can be altered by ER depending on the cell type51.  
E2 affects vessels density, structure, organization and stability with mural cell recruitment and affects 
vessels maturation52. The dilation of blood vessels is also estrogen-regulated. Endothelial nitric oxide 
synthase is stimulated via ERα activation of MAPK pathway. The synthase produces nitric oxide (NO) in 
the pulmonary endothelial cells and the NO production leads to the blood vessels dilatation.  
ERα stimulation of MAPK signaling cascade in other types of cells leads to a different effect. In neuronal 
cells, the stimulation results in neuroprotection after glutamate excitotoxicity, in bone cells, it is essential 
for bone formation by regulating osteoblast proliferation and differentiation42. 
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3.3.5 Role of estrogen signaling in breast carcinoma 
ER represents an advantage for BC lines in several ways. The signaling support, inter alia, tumor 
proliferation and that is why estrogen is considered as a key factor for its growth.  
ERα stimulates genes participating in e.g., proliferation, steroid/xenobiotic metabolism, and ion 
transport. BC cells often depend on E2 in proliferation and cell growth53.  
E2 influence the cell cycle progression via inducing the escape from G1 arrest and pass to the S phase 
due to the cyclin-dependent kinases that are activated by E2 as well54. E2 upregulates expression of the 
genes for cyclin D1, A2, cdc2, cdc20, and Bub1 that are responsible for the progression of the cell cycle 
along with other genes that are also regulated by E2 and genes involved in DNA synthesis53. ERα induces 
expression of c-Myc and downregulates an inhibitor for p27 Kip1 the Cdk2 protein whereas ERβ has the 
opposite effect of their expression. Therefore, ERβ signaling suppresses BC cells proliferation, unlike ERα 
with the opposite effect55. 
E2 improves cell proliferation and tissue development. E2 regulates cell translational regulation via 
estrogen-responsive genes of eukaryotic translation initiation factor 3 subunits. Cell proliferation and 
tissue development are improved. The oncogenes are involved in the growth and/or migration of ER+ BC 
cells56. 
Normal mammary gland development is also based on increased cell proliferation that requires ER 
regulation of transcription factors such as HOXC6 and A-Myb. Whereas HOX6 is downregulated in the 
normal tissue growth, in transformed cells, HOX6 is upregulated via ER cascade. The upregulation gives 
BC cells the advantage of the cell proliferation support53. 
E2 also downregulates several genes. The downregulation of the genes which code the proteins, 
known as the cell cycle inhibitors, enhance proliferation and the cell cycle. The direct inhibitors of the cell 
cycle lowered by E2 are BTG-1, BTG-2, and cyclin G2. The genes coding cytokines and growth factors 
inhibiting cell proliferation (proteins from TGFβ superfamily) are also decreased by ER pathway53. 
The tumor suppressor p53 is under estrogen action control. Efficient growth of the mammary gland 
cells is established by suppression of the p53 activity and consequently the growth-inhibitory proteins 
under p53 control. Additionally, the prolonged exposure to the E2 allows the damaged cells to bypass the 
p53-regulated mechanisms of DNA repair and cell elimination by p53-dependent apoptosis. This can 
ultimately result in the gain of the mutation in p53 itself, a key step in the tumor progression resulting in 
an increased cytotoxic and chemotherapeutic resistance.  
The cell cycle phase control, DNA replication, and repair are estrogen-dependent and cohere with the 
E2 regulation of the gene for transcription, mRNA processing, splicing and transport, ribosome biogenesis, 
protein folding, and degradation54.  
For better fitness, BC cells must avoid cell elimination and that is secured by ER signaling. E2 dependent 
cells have better viability due to the antiapoptotic effect54. The upregulation of the genes for surviving 
inhibits apoptosis53. E2 induces the expression of Bcl-2 protein, therefore, Bcl-2 and Bax ratio changes. 
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The ratio serves as a marker for mitochondria contribution and apoptosis. The protein p53 is a positive 
transcriptional regulator for Bax and negative for Bcl-2. Consequently, E2 decreases the expression of p53 
which affects the regulation of other proteins expression. There is a direct interaction between ERα and 
p53. ERα regulates another protein mdm2 which is responsible for p53 localization and stability49.  
The tumor growth is supported by another remarkable process. E2 can upregulate its own synthesis 
by a feed-forward cascade. ER signaling upregulates prostaglandin E synthetase and prostaglandin E 
receptor type 3 which in consequence increases the synthesis of E253.   
The invasive and metastatic phase of BC is induced by the ER and PR signaling. These receptors are 
involved in carcinogenesis where either of the steroid receptors correlates with the expression of NF-κB 
and tumor necrosis factor alpha (TNF-α). TNF-α is known as a cytokine involved in apoptosis, 
inflammation, and immunity57. 
E2 is also able to induce the creation of new blood vessels. Without the blood supply, the tumor is 
limited and cannot continue in the growth, hence, it is highly dependent on the nutrition that the 
angiogenesis provides. The angiogenic factor TSP-1 is upregulated after the E2 stimulation. E2 regulates 
the balance between pro- and anti-angiogenic factors and via paracrine interactions between endothelial 
cells, tumor cells, and other stromal cells increase the tumor angiogenesis and subsequently, the tumor 
growth. The tumor avoids hypoxia and necrosis by receiving nutrients and oxygen52. 
Hormonal dependent activation of c-Myc leads to the transactivation of the gene for the glucose 
transporter-1 (GLUT1) independently on the hypoxic conditions in the extracellular microenvironment55. 
The c-Myc activity could be enhanced by E2 action directly and eventually by downregulating an inhibitor 
of c-Myc53. 
ERβ signaling normally antagonize ERα response in a way that the ERβ inhibits the pro-angiogenic 
factor PDGFβ leading to the reduction of angiogenesis and consequently the tumor growth is inhibited58. 
ERβ inhibits the metastatic progress via upregulation of the expression of the gene for E-cadherin, a 
molecule responsible for cell-cell interactions58. ERβ signaling inhibits proliferation by repressing c-Myc, 
cyclin D, and cyclin A gene transcription and increase expression of p21, p27 what leads to G2 cell cycle 
arrest49. 
3.2.6 Metabolic regulations related to estrogen signaling in breast carcinoma 
Cancer cells are forced to adapt their features in order to survive. The modifications of cell metabolism 
are one of the key tasks in tumor progression. E2 regulates many of the metabolic pathways. Its signaling 
influence e.g. aerobic glycolysis, nucleotide, and amino acid synthesis, and glycerophospholipid 
metabolism. 
The changes are mediated by ERα via several pathways that include the increase in production of 
metabolic intermediates for biosynthesis and consequently support proliferation59. 
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Glycolysis is E2 dependent metabolic pathway that is regulated via membrane-initiated ER activation 
of PI3K-Akt signaling pathway leading to the upregulation of hexokinase activity and glycolysis60. The 
promoter of the gene for fructose-2,6-biphosphatase 3 (PFKFB3) contains ERE and is controlled by the ER. 
E2 upregulates the protein’s synthesis that leads to the increased levels of fructose 2,6-bisphosphate, the 
product of PFKFB3 enzyme, and glucose uptake. Thanks to these processes, glycolysis is promoted61. 
The usage of metabolism is regulated regarding the current conditions. In conditions with high levels 
of glucose, BC cells use preferably glucose metabolism that is supported by E2 signaling. The signaling 
pathway is mediated by PI3K/Akt activation and stimulates the increase in glucose uptake as well as the 
expression of the genes from the glycolytic pathway. TCA cycle is inhibited due to the decreased pyruvate 
dehydrogenase (PDH) activity leading to low citrate concentrations. The activity of the PDH enzyme is 
important for the transformation of glucose to pyruvate in the TCA. E2 signaling is also responsible for 
the inhibition. If the cell finds itself in low glucose conditions, the opposite response follows. PDH enzyme 
activity increases leading to TCA cycle stimulation while glycolysis is inhibited. All these operations are 
controlled via E2 signaling pathways, although different kinases are used. In lack of glucose, PDH activity 
is stimulated by 5' AMP-activated protein kinase (AMPK), on the other hand, AMPK activity is inhibited by 
AKT action in high glucose concentrations62. 
The common feature of cancer cells is the increase of glutaminolysis compared to the normal cells. 
There is also a difference between ER- (negative) and ER+ (positive) BC cells in the manner of 
glutaminolysis63. Glutamine as a major amino acid in the blood and the major source of nitrogen is also 
connected to the cellular production of ATP by anaplerosis reaction of TCA as well as to the usage as a 
building block for protein and nucleic acid synthesis and antioxidant capacity5. 
The higher growth rate is ensured via the effect of E2 on BC cells leading to increased consumption of 
glucose and glutamine; the lactate levels and PPP flux increase. Glucose is used for both energetic and 
precursors gain. Glutamine is preferentially used as a biosynthetic precursors source instead of oxidizing 
in mitochondria. The PPP flux produces NADPH that is used in biosynthesis. Some glutamine is also used 
for FA synthesis. Also, the increase in glutamine consumption leads to a higher concentration of lactate 
in aerobic conditions64. BC cells also change serine/glycine biosynthesis and metabolism of FA that helps 
the cancer cell in surviving and proliferation5. 
The previously mentioned protooncogene c-Myc has also a different task in the reprograming 






Malate-aspartate shuttle is almost irreversible. Just a small amount of cytosolic malate and NADH are 
transferred to the mitochondrion. NADH is transferred from glycolysis in small doses to the 
mitochondrion. Nevertheless, most of NADH stays in the cytosol; NADH/NAD+ ratio increases and this 
ratio shifts lactate dehydrogenase equilibrium towards lactate64.  
In summary, both aerobic glycolysis and lactate production are amplified. The excretion of malate from 
mitochondrion is preferred instead of mitochondrial consumption. That leads to high cytosolic levels of 
both, aspartate and citrate, the precursors for de novo biosynthesis of nucleosides, proteins, lipids, and 
cholesterol that are needed for the cell growth64.  
Rapidly dividing cells must also replicate their DNA. The excessive synthesis of DNA requires 
supplementation of the nucleotide precursors. The nucleotides are synthesized in one-carbon 
metabolism that needs folate molecules for proper functioning. Folate-synthesis and one-carbon 
metabolism are regulated by E2. Folate metabolism has two options to fuel one-carbon metabolism; 
mitochondrial or cytosolic folate pathway. E2 selectively activates the mitochondrial one 65.  
The polyamine and de novo purine synthesis are also upregulated by E2 due to the regulation of the 
important proteins involved in this pathway. These two are essential for proliferation and migration of 
ER+ (positive) BC cells65. 
The formation and maintenance of vesicular membranes are crucial for proliferating cancer cells.  E2 
supports glycerophospholipid metabolism pathway through the changes in choline metabolism level. The 
levels of phosphocholine (PCho) decrease and the levels of phosphatidylcholine (PtdCho) increase. E2 
signaling in BC cells stimulates choline phosphotransferase 1 (CHPT1) that affects the levels of PtdCho. 
The rate-limiting enzyme in PtdCho synthesis is CCT (CTP: phosphocholine cytidylyltransferase) which 
expression is upregulated in BC. The CCT is considered a metabolic hallmark of cancer. E2 supports the 
synthesis of precursors for subsequent biosynthesis. In E2 signaling cascade, the induction of PtdCho 
production is upregulated thanks to the changed expression of CHPT1 and the increase in precursor 
synsthesis59.  
PCho/GDP ratio is associated with malignant transformation. Lowered levels of CHPT1 leads to the 
reduction of the ratio and in consequence, to the decrease of proliferation and growth of the transferring 
cells. CHPT1 is used in an early stage of metastasis. The upregulation of CHPT1 leads to the higher levels 
of PtdCho and that supports the cell membrane synthesis59. 
The metabolic pathway that supports proliferation via synthesis of amino acids is also beta-alanine 
metabolism. This pathway is increased in BC cells compared to normal tissue. ABAT (4-Aminobutyrate 
aminotransferase) protein expression is up-regulated in ER+ BC. This protein action leads to the 
supplementation of TCA by the synthesis of acetyl-CoA63. 
In BC cells estrogen stimulates expression of ornithine decarboxylase, the enzyme involved in the 
synthesis of polyamines66.  
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There are also alternations in the cancer stem cells (CSCs) energy metabolism. These cells are more 
glycolytic than differentiated tumor cells. More glycolytic cells are usually more aggressive and have 
increased multidrug resistance. Such stimulation causes the induction of anaerobic glycolysis and 
oxidative phosphorylation is slowed down. Stimulating of ERβ leads to apoptosis in adherent BC cells 
through the mitochondrial way, although CSCs are not fully dependent on oxidative respiration, 
therefore, CSCs may benefit from ERβ signaling due to enhanced glycolysis46. 
Lots of these changes could explain resistance to hormone treatment in breast cancer65. The 




4. Resistance to hormone treatment in breast carcinoma 
BC is a hormone responsive disease and ER, as an important regulator in the tumor growth, is 
frequently used as a target of hormone treatment. The cancer response to the endocrine therapy 
correlates with the levels of PR and ER; their expression is linked together57. About 70-75 % of invasive BC 
cells express ER59. The advantage of the treatment is that these two receptors are rare in normal breast 
tissue57.  
Endocrine agents perform the therapeutic effect by changes in angiogenesis, differentiation, invasion, 
and metastasis. The effectiveness of endocrine therapy depends on the efficiency of the induction of cell 
proliferation arrest68. Nowadays, there are two strategies in anti-hormone therapy. First, long-term 
treatment inhibits estrogen-stimulated growth by blocking of tumor ER. Second, the treatment blocks the 
estrogen biosynthesis69. 
4.1    Selective estrogen receptor modulators (SERMs)  
Molecules belonging to this group of pharmaceuticals are used for their ability to antagonize ER. ER-
binding SERM molecule is incapable of making the conformational changes required for recruitment of 
the coactivators and corepressors70. Antiestrogen competes with E2 for the binding spot of the ER.  
Tamoxifen (TAM) is an amino-ether derivate of polycyclic phenol71 metabolized in the human body. 
The metabolization changes molecular features, but it is not required for TAM response72. However, 
metabolism of TAM molecules leads to different affinity to ERα of arose molecules. Some of the 
metabolites have higher and some lower affinity to ERα than TAM73. TAM action is mediated by ER; there 
is a significant correlation between the ER levels and the response to TAM. The loss of ER usually signifies 
the resistance to TAM and is a major reason for developing de novo resistance74.  
The antiestrogen induces the delay in the replenishment of the cytosolic ER; the ER-antiestrogen 
complex interacts differently with chromatin acceptor sites than the ER-E2 complex72. 
Antiestrogens selectively inhibit proliferation of the ER expressing BC cells. Treated cells are arrested 
in the G0-G1 phase of the cell cycle. This arrest is reversible by E2.  Antiestrogens suppress E2 mediated 
stimulation of plasminogen activator activity. Its increase leads to the elevation of metastatic potential of 
tumor cells72. TAM blocks an estrogen-induced increase in PR75. 
4.2    Selective estrogen receptor downregulators (SERDs)  
Resistant tumors to the TAM therapy still respond to another hormone treatment, e.g. SERDs and/or 
aromatase inhibitors (AIs). This suggests ER dependence of these tumors76. Fulvestrant (FVS) is SERD 
prescribed to postmenopausal women who developed resistance to TAM or AIs treatment and have ER+ 
BC77. The steroidal drug FVS is the pure ER antagonist with ERα affinity 100-fold greater than TAM has. 
Moreover, ER-binding FVS inhibits the dimerization and signaling cascade, so it cannot be started78. 
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FVS as the pure anti-estrogen has no known agonistic effect mediated by ER. The conformational 
changes dictated by the bound of FVS that promotes the receptor to degradation. This results in 
downregulation of protein and to depletion of ER transcriptional activity. ER degradation induces the 
reduction of the ER-regulated proteins (e.g., PR, pS2, cell survival protein Bcl-2) and the reduction of 
proliferation. FVS treatment leads to almost complete inhibition of gene transcription. FVS treatment may 
lead to the ER-negative phenotype79. 
TAM blocks the activity of AF-2, AF-1 activity remains the same. Also, TAM acts partially as an agonist. 
On the other hand, after FVS binding to ER, the conformational change occurs, and the change disrupts 
both AF-1 and AF-2 related transcriptional activity80. FVS blocks nuclear localization and inhibits 






Fig. 10. Different action of TAM and FVS. 
 Tamoxifen (T), belonging to the SERM family, inhibits only activation function 2 (AF-2). Activation 
function 1 (AF-1) is still functional and estrogen receptor (ER) is still able to affect the cell growth by 
its signaling and alternations in transcription. T also has a partial agonist effect on ER gene 
transcription. On the other hand, fulvestrant (F), from the SERD family, inhibits both AF-1 and AF-2. F 





4.3    Aromatase inhibitors (AIs) 
Two types of AIs are used as a treatment; steroidal and non-steroidal. The steroidal or so-called type I 
inhibitors are structurally like androstenedione, the substrate for aromatase enzyme. This substance 
binds to the enzyme and is converted to another intermediate that causes irreversible enzyme inhibition 
by its binding. Type II, the non-steroidal AIs, competes for the enzyme with its original substrate83. In 
summary, their effect lies in the inhibition of the enzyme that converts androgens to estrogens called 
aromatase84. 
E2 is mainly synthesized in postmenopausal woman body via the extraglandular conversion of the 
androstenedione (estrogen precursor) to estrone by aromatization. AIs stops the process of aromatization 
and inhibits the E2 production85.  
The function of anti-estrogens lies in obstruction of ER-mediated pathways, however, AIs block also 
ER and overall the production of E2 is significantly lowered. The receptor-independent E2 effect is also 
inhibited. The E2-independent effect lies in the metabolized E2 that can generate oxygen free radicals 
that cause DNA damage or other E2 metabolites causing the DNA alterations86.  
4.4    Mechanism of resistance to hormonal treatment in breast carcinoma 
Hormone therapy brings a significant improvement in BC outcomes. Still, the clinical problem appears 
due to the development of resistance to endocrine therapy in treated cells. Tumor as an evolving process 
response to the hormonal treatment, nevertheless, resistance can be developed. The resistance exists in 
two forms: a) de novo (existing before treatment) or b) acquired (developed during therapy). 
The acquired resistance can be triggered in many ways. One of them is based on a mutation in the 
gene for ER; called ESR1. Mutations in ESR1 lead to receptor-ligand independence and reduce response 
to TAM and FVS in BC. The lack of estrogen, a strong selective pressure, results in the selection of the 
mutated cells in the ESR1 gene, resulting in estrogen-independent growth. This process leads to the 
adaptation to E2 deprivation in vitro. Endocrine resistance is conditioned by mutations in ESR1 and other 
signaling pathways87. 
Another option for the cell to escape estrogen-dependence is via activation of fibroblast growth factor 
receptor (FGFR) 3. Activation of this receptor leads to the promotion of the TAM resistance88. FGFR2 is 
also involved in the development of endocrine resistance. FGFR2 signaling pathway governs the ER 
function and affects the action of TAM. This type of resistance is linked together with microenvironment 
stimuli that start the signal mediated via FGFR289.  
E2 pathway is very complex, so are the pathways to resistance. One of the ways is the alteration of the 
enzyme that metabolizes the drug to its more active form (endoxifen). The mutation in such an enzyme 
slows down the enzymatic activity to the complete inhibition and results in a poorer outcome for the 
patients. ERα serves as a primary target of endocrine therapy. It is known that tumor lacking ERα cannot 
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a response to TAM therapy. The complete protein loss is not necessary. The mutation in the ER gene is 
enough to cause functional ER-negative phenotype in the tumor.  
The alteration of co-regulatory protein in ER action also plays a role in the endocrine resistance. Co-
activators and co-repressors make a complex with ER and induce transcriptional changes in this pathway. 
TAM typically induces the action of co-repressors. Therefore, the altered expression of the co-regulator 
genes may cause resistance. Specifically, overexpression of co-activators leads to TAM resistance due to 
the overexpressed co-activator proteins ability of the enhancement of TAM agonistic activity.  
The overexpression of pro-oncogene HER2 and EGFR are connected to the poorer response to the 
hormonal therapy in ER+ BC cells90,91.  
The mentioned tumor suppressor activity of ERβ signaling is also the reason of endocrine resistance. 
Alteration in ERβ expression is involved in endocrine resistance.  
The endocrine adaptation has a big role in the resistance of pre-menopausal women treated with TAM. 
The levels of estrogen are significantly higher and inhibit saturation of ER with TAM92. The co-activator 
AIB1 is very important in signaling leading to BC cell growth. Moreover, AIB1 acts as an enhancer of the 
agonistic activity of TAM. This may lead to resistance93. 
Also, the cell can develop TAM-stimulation features. These tumor cells grow in the response to either 




Breast cancer is an oncological disease that includes various phenotypes that are difficult to classify 
into the subgroups. The heterogeneity of phenotypes ensures the large variability of the cells.  
The leading force of BC progression is stimulated via the estrogen receptor. The E2 signaling changes 
cell behavior to rapid progression and invasiveness.    
BC cells are characterized, as most of the cancer cells in general, by alterations in the metabolic 
pathways. These changes are distinctive for the cancer cells and differ from normal cells of a human body. 
Cancer cells can preferentially use other energy sources than normal cells.  
The plastic metabolism results from the sorting to BC subtypes. Cell metabolism also depends on 
other things: cell localization, nutrition concentration, and the metastatic phase. 
Nowadays, there is a treatment that is effective in specific BC subgroups, the ER-positive tumors. The 
hormone treatment is based on the inhibition of estrogen signaling in tumor cells, which can be achieved  
by the inhibition of ER signaling via binding of an antagonist or by the inhibition of estrogen synthesis. 
About 30-40 % of postmenopausal breast cancer women respond to the hormone manipulation95. 
However, the treated tumors can develop resistance. The resistance can evolve in different ways, but 
the mechanism has not been fully discovered yet. To avoid the resistant tumor progression, it is important 
to find the new targets for cancer therapy.  
BC cannot be considered as a single disease entity. The determination of BC subtype is conditional for 
the right selection of therapy.  
Different metabolic requirements of cancer cells can be used in treatment. The therapy target must 
be exclusive for the cancer cell to decrease the toxicity the treatment may cause. Breast cancer is 
considered a metabolic disease. That is why the metabolic drug target can be found among the metabolic 
alterations in BC cells in metabolic pathways that are critical for BC proliferation. For example, in one-
carbon folate metabolism that is steered via the mitochondrial pathway in BC cells. Also, de novo purine 
synthesis pathway that can be used in treatment targeting65. CHPT1, the important enzyme in choline 
metabolism, is overexpressed in BC cells and it is another possible target59. Another intervention site of 
the drugs can be found among the enzymes from PPP64 and glutaminolysis63,64. There are also drugs 
targeting glycolysis, fatty acid synthesis,  HIF signaling63.  
A better understanding of cancer cells and their unique features can be used in both the cancer 




6. List of abbreviations  
AF-1  Activation function 1  
AF-2  Activation function 2  
AIs  Aromatase inhibitors  
AMPK  5' AMP-activated protein kinase  
ASCT2  Glutamine transporter  
BC  Breast cancer 
BM  Basal membrane 
CHPT1  Choline phosphotransferase 1 
CSC  Cancer stem cell 
CTC  Circulating tumor cell 
DBD  DNA binding domain 
DCIS  Ductal carcinoma in situ  
DRC  DNA repair capacity 
E2  17-β-estradiol  
ECM  Extracellular matrix  
EMT  Epithelial-mesenchymal transition  
EndMT  Endothelial-mesenchymal transition 
ER-   Estrogen receptor negative 
ER  Estrogen receptor 
ER+  Estrogen receptor positive 
ERE  Estrogen responsive element 
FA  Fatty acid  
FGFR  Fibroblast growth factor receptor 
FVS  Fulvestrant 
GLS  Glutaminase 
GLUT  Glucose transporter 
HIF  Hypoxia-inducible factor 
HR  Homologous recombination 
IDC  Invasive ductal carcinoma  
IS  Immune system  
LBD  Ligand binding domain 
LCIS  Lobular carcinoma in situ  
MAPK  Mitogen-activated protein kinase 
MET  Mesenchymal-epithelial transformation 
NF-κB  Nuclear factor κB 
NLS  Nuclear localization signal 
NO  Nitric oxide  
NOD-like Nucleotide-binding oligomerization domain-like 
OXPHOS Oxidative phosphorylation  
PC  Pyruvate carboxylase 
PDH  Pyruvate dehydrogenase 
PFKFB3  Fructose-2,6-biphosphatase 3 
PI3K/Akt Phosphoinositide 3-kinases/protein kinase B 
PPP  Pentose phosphate pathway 
PR   Progesterone receptor 
SERDs  Selective estrogen receptor downregulators 
SERMs  Selective estrogen receptor modulators  
TAM  Tamoxifen 
TCA  Tricarboxylic acid cycle 
TNBC  Triple-negative breast cancer 
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